Back to Journals » International Journal of Nanomedicine » Volume 5

Antitumor activity of silver nanoparticles in Dalton’s lymphoma ascites tumor model

Authors Sriram MI, Kanth SBM, Kalishwaralal K, Gurunathan S

Published 24 September 2010 Volume 2010:5 Pages 753—762

DOI https://doi.org/10.2147/IJN.S11727

Review by Single-blind

Peer reviewer comments 2

Muthu Irulappan Sriram, Selvaraj Barath Mani Kanth, Kalimuthu Kalishwaralal, Sangiliyandi Gurunathan
Department of Biotechnology, Division of Molecular and Cellular Biology, Kalasalingam University, Tamilnadu, India

Abstract: Nanomedicine concerns the use of precision-engineered nanomaterials to develop novel therapeutic and diagnostic modalities for human use. The present study demonstrates the efficacy of biologically synthesized silver nanoparticles (AgNPs) as an antitumor agent using Dalton’s lymphoma ascites (DLA) cell lines in vitro and in vivo. The AgNPs showed dose-dependent cytotoxicity against DLA cells through activation of the caspase 3 enzyme, leading to induction of apoptosis which was further confirmed through resulting nuclear fragmentation. Acute toxicity, ie, convulsions, hyperactivity and chronic toxicity such as increased body weight and abnormal hematologic parameters did not occur. AgNPs significantly increased the survival time in the tumor mouse model by about 50% in comparison with tumor controls. AgNPs also decreased the volume of ascitic fluid in tumor-bearing mice by 65%, thereby returning body weight to normal. Elevated white blood cell and platelet counts in ascitic fluid from the tumor-bearing mice were brought to near-normal range. Histopathologic analysis of ascitic fluid showed a reduction in DLA cell count in tumor-bearing mice treated with AgNPs. These findings confirm the antitumor properties of AgNPs, and suggest that they may be a cost-effective alternative in the treatment of cancer and angiogenesis-related disorders.

Keywords: antitumor, silver nanoparticles, Dalton’s lymphoma, ascites

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]